HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $2.50 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 208.64% from the company’s previous close.

Separately, Alliance Global Partners raised shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st.

IceCure Medical Stock Performance

Shares of NASDAQ:ICCM traded up $0.02 during midday trading on Wednesday, hitting $0.81. The stock had a trading volume of 160,944 shares, compared to its average volume of 580,506. The stock has a 50 day moving average price of $0.64 and a two-hundred day moving average price of $0.72. The company has a market capitalization of $36.95 million, a PE ratio of -2.73 and a beta of 0.48. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.57. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC acquired a new position in IceCure Medical Ltd (NASDAQ:ICCM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.